17 completed. 17 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 17 | Completed 17 |
Follow GERD: new trials by email Literature Review of GERD trials Research Report on GERD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Obesity on Proton Pump Inhibitors Lansoprazole, Pantoprazole, Midazolam - Pediatric Obesity, NAFLD | Phase 4 | Completed | Children's Mercy Hospital Kansas City | 76 | 2018-07-03 | 2026-06-04 |
| Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS Neobianacid®, Omeprazole 20mg, Neobianacid® placebo - GERD, EPS | Phase 4 | Completed | Aboca Spa Societa' Agricola | 275 | 2017-09-12 | 2022-11-21 |
| An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan Dexlansoprazole 60 MG - GERD, Proton Pump Inhibitor | Phase 4 | Completed | American University of Beirut Medical Center | 33 | 2017-02-27 | 2017-09-15 |
| Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases OMEZ 40, OMEZ 80 - GERD | Phase 4 | Completed | Dr. Reddy's Laboratories Limited | 120 | 2013-01-01 | 2016-10-04 |
| To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole esomeprazole 20 mg - Gastroesophageal Reflux Disease, GERD | Phase 4 | Completed | AstraZeneca | 107 | 2011-08-01 | 2013-02-21 |
| Does Omeprazole Decrease Intestinal Calcium Absorption? Omeprazole - Osteoporosis, Achlorhydria | Phase 4 | Completed | University of Wisconsin, Madison | 23 | 2008-01-01 | 2013-02-15 |
| Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients esomeprazole (Nexium®), Xolaam® - GERD | Phase 4 | Completed | AstraZeneca | 3029 | 2007-03-01 | 2012-12-11 |
| Nexium RESPONSE Trial Esomeprazole - GERD | Phase 4 | Completed | AstraZeneca | 1000 | 2006-05-01 | 2009-01-26 |
| Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD Antacids - GERD | Phase 4 | Completed | Digestive & Liver Disease Specialists | 50 | 2005-10-01 | 2009-02-25 |
| An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Esomeprazole - GERD | Phase 4 | Completed | AstraZeneca | 350 | 2005-10-01 | 2009-03-06 |
| The Utility of Nexium in Chronic Cough and Reflux Disease Esomeprazole, Placebo - Cough, GERD | Phase 4 | Completed | University of North Carolina, Chapel Hill | 40 | 2005-09-01 | 2012-01-10 |
| Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506) Pantoprazole - Gastroesophageal Reflux, GERD | Phase 4 | Completed | Takeda | 300 | 2005-08-01 | 2012-05-07 |
| CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing rabeprazole - GERD | Phase 4 | Completed | National Taiwan University Hospital | 200 | 2005-06-01 | 2012-12-03 |
| Sleep Disorders and Gastroesophageal Reflux Disease (GERD) Rabeprazole - Insomnia, GERD | Phase 4 | Completed | University of North Carolina | 20 | 2004-09-01 | 2007-04-27 |
| PPI Test in GP Patients Esomeprazole, Ambulatory 24-hour esophageal pH-monitoring - GERD | Phase 4 | Completed | AstraZeneca | 100 | 2003-01-01 | 2007-08-17 |
| An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Esomeprazole - GERD | Phase 4 | Completed | AstraZeneca | 60 | 2002-09-01 | 2011-01-25 |
| Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously Esomeprazole - GERD | Phase 4 | Completed | AstraZeneca | 60 | 2002-08-01 | 2011-01-25 |
Gastroesophageal Reflux (17) · Heartburn (2) · Achlorhydria (1) · Cough (1) · Esophagitis, Peptic (1) · Hip Fractures (1) · Non-alcoholic Fatty Liver Disease (1) · Osteoporosis (1) · Parasomnias (1) · Pediatric Obesity (1) · Sleep Initiation and Maintenance Disorders (1)
Deglutition Disorders (17) · Digestive System Diseases (17) · Esophageal Diseases (17) · Esophageal Motility Disorders (17) · Gastrointestinal Diseases (17) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Nutritional and Metabolic Diseases (2) · Signs and Symptoms, Digestive (2) · Stomach Diseases (2) · Acid-Base Imbalance (1) · Body Weight (1) · Bone Diseases (1) · Bone Diseases, Metabolic (1) · Duodenal Diseases (1)
Esomeprazole (8) · Omeprazole (3) · Pantoprazole (2) · Rabeprazole (2) · Ambulatory Care Facilities (1) · Antacids (1) · Dexlansoprazole (1) · Lansoprazole (1) · Midazolam (1)
AstraZeneca (7) · Aboca Spa Societa' Agricola (1) · American University of Beirut Medical Center (1) · Children's Mercy Hospital Kansas City (1) · Digestive & Liver Disease Specialists (1) · Dr. Reddy's Laboratories Limited (1) · National Taiwan University Hospital (1) · Takeda (1) · University of North Carolina (1) · University of North Carolina, Chapel Hill (1) · University of Wisconsin, Madison (1)
United States (6) · Denmark (1) · France (1) · Italy (1) · Lebanon (1) · Netherlands (1) · Taiwan (1) · United Kingdom (1)
Nicholas Shaheen, MD, MPH (2) · David A Johnson, MD (1) · Karen E Hansen, MD (1) · Kathryn Kyler, MD, MS (1) · Makiko Abe (1) · Masataka Date (1) · Ming-Shiang Wu, PHD (1) · Paula Fernstrom (1) · Stig Waldorff, MD (1) · V.D Pasechnikov, MD (1) · Villy Meineche Schmidt, MD (1)
PMID 19601705, PMID 20578215, PMID 21083590, PMID 21083673, PMID 21347742, PMID 22759841, PMID 30625462, PMID 37307528, PMID 42226497
K23DK115827 (1)